Gastric Xanthomas and Fundic Gland Polyps as Endoscopic Risk Indicators of Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Fundic gland polyps (FGPs), hyperplastic polyps (HPs), and xanthomas (XTs) are common benign gastric lesions that can be diagnosed by endoscopic appearance alone in most cases. The aim of this study was to evaluate associations between gastric cancer and these benign lesions. Methods: Two expert endoscopists reviewed a series of gastroscopy images. FGPs, HPs, and XTs were diagnosed by endoscopic appearance, whereas all gastric cancers were confirmed pathologically. Results: Of the 1,227 patients reviewed, 114 (9.3%) had a concurrent or past history of gastric cancer. The overall prevalences of FGPs, HPs and XTs were 9.4%, 6.3% and 14.2%, respectively. HPs and XTs coexisted in 1.6% of patients, whereas other combinations were rarer. XTs were observed in 39.3% and 11.5% of patients with and without gastric cancer, respectively (p<0.001). In contrast, no gastric cancer patients had FGPs, whereas 10.4% of patients without cancer had FGPs (p<0.001). The prevalence of HPs was similar between the two groups (8.8% and 6.0% of patients with and without cancer, respectively, p=0.29). Multivariate and Mantel-Haenszel analyses demonstrated that XTs were positively associated and FGPs were negatively associated with gastric cancer. Conclusions: XTs and FGPs might be useful as endoscopic risk indicators for monitoring gastric cancer.
Abstract
Background/Aims: Fundic gland polyps (FGPs), hyperplastic polyps (HPs), and xanthomas (XTs) are common benign gastric lesions that can be diagnosed by endoscopic appearance alone in most cases. The aim of this study was to evaluate associations between gastric cancer and these benign lesions. Methods: Two expert endoscopists reviewed a series of gastroscopy images. FGPs, HPs, and XTs were diagnosed by endoscopic appearance, whereas all gastric cancers were confirmed pathologically. Results: Of the 1,227 patients reviewed, 114 (9.3%) had a concurrent or past history of gastric cancer. The overall prevalences of FGPs, HPs and XTs were 9.4%, 6.3% and 14.2%, respectively. HPs and XTs coexisted in 1.6% of patients, whereas other combinations were rarer. XTs were observed in 39.3% and 11.5% of patients with and without gastric cancer, respectively (p<0.001). In contrast, no gastric cancer patients had FGPs, whereas 10.4% of patients without cancer had FGPs (p<0.001). The prevalence of HPs was similar between the two groups (8.8% and 6.0% of patients with and without cancer, respectively, p=0.29). Multivariate and Mantel-Haenszel analyses demonstrated that XTs were positively associated and FGPs were negatively associated with gastric cancer. Conclusions: XTs and FGPs might be useful as endoscopic risk indicators for monitoring gastric cancer.
참고문헌 (21)
- "Infection with Helicobacter pylori", IARC Monogr Eval Carcinog Risks Hum, 61, pp.177~240 (1994)
- Kato S, "Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients : incidence and pathological characteristics", Cancer Sci, 98, pp.790~794 (2007)
- Kang HY, "Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa", Dig Dis Sci, 51, pp.2310~2315 (2006)
- Ohata H, "Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer", Int J Cancer, 109, pp.138~143 (2004)
- Lahner E, "Long-term follow-up in atrophic body gastritis patients : atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection", Aliment Pharmacol Ther, 22, pp.471~481 (2005)
- Redéen S, "Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample", Endoscopy, 35, pp.946~950 (2003)
- Gonen C, "Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of Helicobacter pylori gastritis in routine clinical practice : a prospective study", Helicobacter, 14, pp.12~21 (2009)
- Carmack SW, "The current spectrum of gastric polyps : a 1-year national study of over 120, 000 patients", Am J Gastroenterol, 104, pp.1524~1532 (2009)
- Isomoto H, "A close relationship between Helicobacter pylori infection and gastric xanthoma", Scand J Gastroenterol, 34, pp.346~352 (1999)
- Goddard AF, "The management of gastric polyps", Gut, 59, pp.1270~1276 (2010)
- Ohkusa T, "Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori : a randomized, clinical trial", Ann Intern Med, 129, pp.712~715 (1998)
- Jain R, "Gastric hyperplastic polyps : a review", Dig Dis Sci, 54, pp.1839~1846 (2009)
- Genta RM, "No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100, 000 patients", Clin Gastroenterol Hepatol, 7, pp.849~854 (2009)
- Hori S, "Helicobacter pylori infection in gastric xanthomas : immunohistochemical analysis of 145 lesions", Pathol Int, 46, pp.589~593 (1996)
- Dirschmid K, "Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa", Virchows Arch, 448, pp.80~84 (2006)
- Matsuo T, "Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese", Helicobacter, 16, pp.415~419 (2011)
- Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 1, pp.87~97 (1969)
- Sekikawa A, "Gastric xanthelasma may be a warning sign for the presence of early gastric cancer", J Gastroenterol Hepatol, 29, pp.951~956 (2014)
- Sekikawa A, "Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer", J Gastroenterol, 51, pp.35~42 (2016)
- Jalving M, "Increased risk of fundic gland polyps during longterm proton pump inhibitor therapy", Aliment Pharmacol Ther, 24, pp.1341~1348 (2006)
- Vieth M, "Fundic gland polyps are not induced by proton pump inhibitor therapy", Am J Clin Pathol, 116, pp.716~720 (2001)